Buccal Drug Delivery System Market Outlook Highlights Strategic Opportunities Across The Industry

The buccal drug delivery system sector is poised for substantial expansion in the coming years, driven by advances in drug formulation and delivery technologies. As researchers and companies focus more on innovative approaches to medication administration, this market is set to experience remarkable growth. Below, we explore its projected size, key players, current trends, and the main segments shaping the industry.

Projected Expansion of the Buccal Drug Delivery System Market
The buccal drug delivery system market is anticipated to grow significantly, reaching a valuation of $6.48 billion by 2030. This represents a compound annual growth rate (CAGR) of 10.7%. The expected surge is fueled by escalating investments in transmucosal drug research, increasing demand for therapies to help quit smoking, and the broadening adoption of personalized drug delivery methods. Additionally, a stronger emphasis on formulations that enhance patient compliance and the development of new buccal drugs are key contributors to this growth. Important market trends include the rising use of buccal and sublingual dosage forms, accelerated demand for rapid drug absorption technologies, prioritization of patient-friendly delivery systems, growth in controlled-release buccal formulations, and a heightened focus on non-invasive therapeutic options.

Download a free sample of the buccal drug delivery system market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8290&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Top Companies Leading the Buccal Drug Delivery System Market
The industry features several prominent companies shaping its direction, including Teva Pharmaceuticals Industries Ltd, Pfizer Incorporated, GlaxoSmithKline Public Limited Company, Indivior PLC, ere*x Biotechnology Corporation, Catalent Inc, Arx Limited Liability Company, BioDelivery Science International Incorporated, Cynapsus Therapeutics Incorporated, Endo Pharmaceuticals Public Limited Company, Medlab Clinical Ltd, AstraZeneca PLC, Dr. Reddy's Laboratories Ltd, Takeda Pharmaceutical Company Limited, Novartis AG, Sanofi SA, Bayer AG, Adare Pharmaceuticals Inc, NAPP Pharmaceutical Ltd, Perrigo Company PLC, Reckitt Benckiser Group PLC, Teligent Pharma Inc, Par Pharmaceutical Companies Inc, Acorda Therapeutics Inc, and Opiant Pharmaceuticals Inc.

Strategic Acquisition to Enhance Market Position
In April 2023, DifGen Pharmaceuticals LLC, a US-based firm, acquired Aveva Drug Delivery Services Inc., in a deal whose financial details were undisclosed. This move aims to provide patients with consistent access to affordable and high-quality life-saving medicines. The acquisition has enabled DifGen to boost its research and development and manufacturing capabilities while ensuring reliable supply chains and the ability to produce complex dosage forms domestically in the US. Aveva Drug Delivery Services specializes in buccal drug delivery, making this partnership a valuable asset for DifGen's growth strategy.

View the full buccal drug delivery system market report:
https://www.thebusinessresearchcompany.com/report/buccal-drug-delivery-system-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Current Trends Shaping the Buccal Drug Delivery System Market
Many leading companies are prioritizing the launch of innovative products, such as melatonin oral sprays, to capture greater market share. Melatonin sprays offer a convenient way to supplement the body's natural hormone production, improving sleep quality effectively. For example, in February 2023, Arlak Biotech Private Limited from India introduced a melatonin oral spray that supports better sleep onset and maintenance. This product's rapid oral absorption offers a swift therapeutic effect, appealing to individuals who struggle with falling asleep, staying asleep, or adjusting their sleep patterns.

Innovations Highlighting Patient-Centric Drug Delivery
The growing focus on ease of use and fast absorption is driving the development of buccal drug delivery systems that prioritize patient comfort and compliance. The convenience of sprays and rapidly dissolving tablets aligns with the increasing demand for non-invasive, user-friendly medication options, opening new avenues for treatment modalities in various therapeutic areas.

Key Segments Defining the Buccal Drug Delivery System Market
This market is segmented into several important categories:
1) By Type: Sublingual, Buccal Tablets and Lozenges, and Oral Sprays
2) By Application: Pain Management, Smoking Cessation, and Angina Pectoris
3) By End-User: Hospitals, Ambulatory Centers, and Other End-Users

Further detailed subcategories include:
- Sublingual: Sublingual Tablets and Sublingual Films
- Buccal Tablets and Lozenges: Buccal Tablets and Buccal Lozenges
- Oral Sprays: Spray Solutions and Spray Gels

These classifications help in understanding product types, therapeutic uses, and the primary markets served, providing a comprehensive picture of the buccal drug delivery system industry's structure and scope.

Key enhancements in our 2026 market reports include:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.